ABSTRACT
Background: Contemplating the severity of pandemic sequel for public health many researchers are working recklessly for new targeted drugs and vaccines. Despite the challenging opportunities, the setup for the development of new effective remedy against COVID-19 is unforeseeable.
ABSTRACT
Introduction: Remdesivir and Tocilizumab are two experimental drugs used in severely ill COVID-19 patients. Various clinical trials studying these drugs are giving conflicting results. Our aim is to study these two drugs and share the experience in our setting. Methods: Our Study is a retrospective analysis of Clinico-laboratory details and outcome of three groups of patients who were given either (i) Remdesivir or (ii) Tocilizumab or (iii)both Remdesivir and Tocilizumab . We compared the outcome of these patients with other patients who did not receive either of these drugs, when it was not available or not introduced as experimental drugs earlier in treatment guidelines. Results: Out of a total of 521 patients, in the above three groups who received either or both Remdesivir or Tocilizumab, 334 survived. Out of 214 patients who did not receive any of the two drugs only 74 survived. The outcome was better individually for all the three groups of patients receiving either or both of the drugs as compared to neither of the drugs.(p <0.01) Conclusion: Remdesivir and Tocilizumab were useful drugs in treatment of severely ill covid -19 patients as compared with the patients who did not receive any of the above drugs. © 2021 Journal of Association of Physicians of India. All rights reserved.
ABSTRACT
COVID-19 pandemic which has spread to 216 countries in eight months resulted in 7.50 lakh deaths across the globe. SARS CoV-2, highly infectious causative agent of this disease is transmitted through droplets, contact routes and aerosols. Even the most developed nations are experiencing difficulty to limit its spread and the disease is still spreading at an alarming rate. For filling the gaps and lacunas in the healthcare system this is high time to integrate different healthcare systems available to meet the ever emerging health challenges. Ayurveda has documented the first reference of epidemics as Janapadodhwamsa and has given a scientific insight to its causes, effect and prevention along with management strategies. No established and approved treatment of COVID-19 is yet available and off label drugs are being tried for prophylaxis and therapeutic purpose. Variation in host susceptibility and outcomes has been observed and host factors are being explored along with fast track vaccine development. Ayurveda treatment always take into account the host factors to alleviate the disease by improving the Agni and providing nutrition and strength to the host by means of Rasayana, Panchakarma, lifestyle measures and using drugs of varied origin. The clinical profile of COVID-19 matches with Vata-Kapha dominant Sannipataja Jwara for which detailed treatment guidelines and array of pharmaceutical preparations are described in Ayurvedic literature which are being practiced by qualified Ayurvedic physicians effectively since long. This paper highlights the Ayurvedic perspective of the COVID-19 along with its prevention, prophylaxis and management strategies through Ayurveda.